Researchers find new benefits, risks in GLP-1 weight loss drugs

Key Points:

• GLP-1 drugs, used for weight loss for about five years, have shown unexpected benefits including reduced alcohol desire, improved arthritis symptoms, and cardiovascular improvements beyond just weight loss.
• Researchers note that GLP-1 drugs may reduce inflammation and improve heart health independently of weight loss, and these drugs might already be prescribed off-label for inflammation despite unknown effects in non-approved populations.
• Adverse effects include vitamin deficiencies due to reduced eating, loss of enjoyment in eating (hedonia), muscle and bone loss, especially concerning for frail patients, prompting research into mitigation strategies like protein intake and resistance exercise.
• A new drug, retatrutide, combining GLP-1, GIP, and glucagon, is in phase three trials and has shown weight loss comparable to bariatric surgery (25-30%), though with increased side effects; it could be approved in the next few years.
• GLP-1 drugs are generally safe when prescribed correctly, but weight loss effects cease after stopping the drug unless accompanied by lifestyle changes; ongoing development aims for more targeted treatments with fewer side effects and longer dosing intervals.